Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017, Article ID 4582135, 14 pages
https://doi.org/10.1155/2017/4582135
Research Article

Loss of Sigma-1 Receptor Chaperone Promotes Astrocytosis and Enhances the Nrf2 Antioxidant Defense

1Genomics Research Center, Academia Sinica, Taipei, Taiwan
2Cellular Pathobiology Section, Integrative Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, Department of Health and Human Services, National Institutes of Health, Baltimore, MD 21224, USA

Correspondence should be addressed to Shang-Yi A. Tsai; vog.hin.liam@iasts

Received 31 March 2017; Revised 9 June 2017; Accepted 28 June 2017; Published 14 August 2017

Academic Editor: Mark G. Waugh

Copyright © 2017 Tzu-Yu Weng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Hayashi and M. Fujimoto, “Detergent-resistant microdomains determine the localization of sigma-1 receptors to the endoplasmic reticulum-mitochondria junction,” Molecular Pharmacology, vol. 77, no. 4, pp. 517–528, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Kourrich, T. Hayashi, J. Y. Chuang, S. Y. Tsai, T. P. Su, and A. Bonci, “Dynamic interaction between sigma-1 receptor and Kv1.2 shapes neuronal and behavioral responses to cocaine,” Cell, vol. 152, no. 1-2, pp. 236–247, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Y. Tsai, M. J. Pokrass, N. R. Klauer, N. E. D. Credico, and T. P. Su, “Sigma-1 receptor chaperones in neurodegenerative and psychiatric disorders,” Expert Opinion on Therapeutic Targets, vol. 18, no. 12, pp. 1461–1476, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. R. R. Matsumoto, “Targeting sigma receptors: novel medication development for drug abuse and addiction,” Expert Review of Clinical Pharmacology, vol. 2, no. 4, pp. 351–358, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. T. P. Su, T. C. Su, Y. Nakamura, and S. Y. Tsai, “The sigma-1 receptor as a pluripotent modulator in living systems,” Trends in Pharmacological Sciences, vol. 37, no. 4, pp. 262–278, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. C. P. Palmer, R. Mahen, E. Schnell, M. B. Djamgoz, and E. Aydar, “Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines,” Cancer Research, vol. 67, no. 23, pp. 11166–11175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Y. Tsai, T. Hayashi, T. Mori, and T. P. Su, “Sigma-1 receptor chaperones and diseases,” Central Nervous System Agents in Medicinal Chemistry, vol. 9, no. 3, pp. 184–189, 2009. View at Publisher · View at Google Scholar
  8. T. Hayashi and T. P. Su, “Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival,” Cell, vol. 131, no. 3, pp. 596–610, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Mori, T. Hayashi, E. Hayashi, and T. P. Su, “Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival,” PLoS One, vol. 8, no. 10, article e76941, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Y. Tsai, M. J. Pokrass, N. R. Klauer, H. Nohara, and T. P. Su, “Sigma-1 receptor regulates tau phosphorylation and axon extension by shaping p35 turnover via myristic acid,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 21, pp. 6742–6747, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Y. Tsai, J. Y. Chuang, M. S. Tsai et al., “Sigma-1 receptor mediates cocaine-induced transcriptional regulation by recruiting chromatin-remodeling factors at the nuclear envelope,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 47, pp. E6562–E6570, 2015. View at Publisher · View at Google Scholar
  12. A. van Waarde, A. A. Rybczynska, N. K. Ramakrishnan, K. Ishiwata, P. H. Elsinga, and R. A. Dierckx, “Potential applications for sigma receptor ligands in cancer diagnosis and therapy,” Biochimica et Biophysica Acta, vol. 1848, no. 10, Part B, pp. 2703–2714, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Aydar, P. Onganer, R. Perrett, M. B. Djamgoz, and C. P. Palmer, “The expression and functional characterization of sigma (sigma) 1 receptors in breast cancer cell lines,” Cancer Letters, vol. 242, no. 2, pp. 245–257, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Gueguinou, D. Crottes, A. Chantome et al., “The SigmaR1 chaperone drives breast and colorectal cancer cell migration by tuning SK3-dependent Ca2+ homeostasis,” Oncogene, vol. 36, no. 25, pp. 3640–3647, 2017. View at Publisher · View at Google Scholar
  15. D. Das, L. Persaud, J. Dejoie et al., “Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) activates caspases in human prostate cancer cells through sigma 1 receptor,” Biochemical and Biophysical Research Communications, vol. 470, no. 2, pp. 319–323, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Happy, J. Dejoie, C. K. Zajac et al., “Sigma 1 receptor antagonist potentiates the anti-cancer effect of p53 by regulating ER stress, ROS production, Bax levels, and caspase-3 activation,” Biochemical and Biophysical Research Communications, vol. 456, no. 2, pp. 683–688, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Hayashi and T. P. Su, “Sigma-1 receptors (σ1 binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export,” The Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 2, pp. 718–725, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. J. T. Vollrath, A. Sechi, A. Dreser et al., “Loss of function of the ALS protein SigR1 leads to ER pathology associated with defective autophagy and lipid raft disturbances,” Cell Death & Disease, vol. 5, article e1290, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Cao, M. P. Walker, N. K. Vaidya, M. Fu, S. Kumar, and A. Kumar, “Cocaine-mediated autophagy in astrocytes involves sigma 1 receptor, PI3K, mTOR, Atg5/7, Beclin-1 and induces type II programed cell death,” Molecular Neurobiology, vol. 53, no. 7, pp. 4417–4430, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. Z. Wu, L. Li, L. T. Zheng, Z. Xu, L. Guo, and X. Zhen, “Allosteric modulation of sigma-1 receptors by SKF83959 inhibits microglia-mediated inflammation,” Journal of Neurochemistry, vol. 134, no. 5, pp. 904–914, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Peviani, E. Salvaneschi, L. Bontempi et al., “Neuroprotective effects of the sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation,” Neurobiology of Disease, vol. 62, pp. 218–232, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. K. T. Tchedre and T. Yorio, “Sigma-1 receptors protect RGC-5 cells from apoptosis by regulating intracellular calcium, Bax levels, and caspase-3 activation,” Investigative Ophthalmology & Visual Science, vol. 49, no. 6, pp. 2577–2588, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Y. Tsai, T. Hayashi, B. K. Harvey et al., “Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1xGTP pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 52, pp. 22468–22473, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Al-Saif, F. Al-Mohanna, and S. Bohlega, “A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis,” Annals of Neurology, vol. 70, no. 6, pp. 913–919, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Watanabe, H. Ilieva, H. Tamada et al., “Mitochondria-associated membrane collapse is a common pathomechanism in SIGMAR1- and SOD1-linked ALS,” EMBO Molecular Medicine, vol. 8, no. 12, pp. 1421–1437, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Mishina, M. Ohyama, K. Ishii et al., “Low density of sigma1 receptors in early Alzheimer’s disease,” Annals of Nuclear Medicine, vol. 22, no. 3, pp. 151–156, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Bernard-Marissal, J. J. Medard, H. Azzedine, and R. Chrast, “Dysfunction in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1 loss of function mediated motor neuron degeneration,” Brain, vol. 138, Part 4, pp. 875–890, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. T. A. Mavlyutov, M. L. Epstein, Y. I. Verbny et al., “Lack of sigma-1 receptor exacerbates ALS progression in mice,” Neuroscience, vol. 240, pp. 129–134, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Francardo, F. Bez, T. Wieloch, H. Nissbrandt, K. Ruscher, and M. A. Cenci, “Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism,” Brain, vol. 137, Part 7, pp. 1998–2014, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. A. V. Molofsky, R. Krencik, E. M. Ullian et al., “Astrocytes and disease: a neurodevelopmental perspective,” Genes & Development, vol. 26, no. 9, pp. 891–907, 2012. View at Publisher · View at Google Scholar
  31. Y. Chen and R. A. Swanson, “Astrocytes and brain injury,” Journal of Cerebral Blood Flow and Metabolism, vol. 23, no. 2, pp. 137–149, 2003. View at Publisher · View at Google Scholar
  32. M. Pekny, U. Wilhelmsson, and M. Pekna, “The dual role of astrocyte activation and reactive gliosis,” Neuroscience Letters, vol. 565, pp. 30–38, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. N. J. Maragakis and J. D. Rothstein, “Mechanisms of disease: astrocytes in neurodegenerative disease,” Nature Clinical Practice. Neurology, vol. 2, no. 12, pp. 679–689, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Y. Moon, D. H. Roh, S. Y. Yoon et al., “Sigma1 receptors activate astrocytes via p38 MAPK phosphorylation leading to the development of mechanical allodynia in a mouse model of neuropathic pain,” British Journal of Pharmacology, vol. 171, no. 24, pp. 5881–5897, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Zhang, X. Lv, Y. Bai et al., “Involvement of sigma-1 receptor in astrocyte activation induced by methamphetamine via up-regulation of its own expression,” Journal of Neuroinflammation, vol. 12, p. 29, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Wang, A. Shanmugam, S. Markand, E. Zorrilla, V. Ganapathy, and S. B. Smith, “Sigma 1 receptor regulates the oxidative stress response in primary retinal Müller glial cells via NRF2 signaling and system xc, the Na+-independent glutamate-cystine exchanger,” Free Radical Biology and Medicine, vol. 86, pp. 25–36, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Uttara, A. V. Singh, P. Zamboni, and R. T. Mahajan, “Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options,” Current Neuropharmacology, vol. 7, no. 1, pp. 65–74, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Pal, D. Fontanilla, A. Gopalakrishnan, Y. K. Chae, J. L. Markley, and A. E. Ruoho, “The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements,” European Journal of Pharmacology, vol. 682, no. 1–3, pp. 12–20, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Y. Tsai, R. K. Rothman, and T. P. Su, “Insights into the sigma-1 receptor chaperone’s cellular functions: a microarray report,” Synapse, vol. 66, no. 1, pp. 42–51, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. J. A. Johnson, D. A. Johnson, A. D. Kraft et al., “The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration,” Annals of the New York Academy of Sciences, vol. 1147, pp. 61–69, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. M. J. Calkins, D. A. Johnson, J. A. Townsend et al., “The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease,” Antioxidants & Redox Signaling, vol. 11, no. 3, pp. 497–508, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. N. Morioka, H. Abe, R. Araki et al., “A beta 1/2 adrenergic receptor-sensitive intracellular signaling pathway modulates CCL2 production in cultured spinal astrocytes,” Journal of Cellular Physiology, vol. 229, no. 3, pp. 323–332, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. N. D. Camp, R. G. James, D. W. Dawson et al., “Wilms tumor gene on X chromosome (WTX) inhibits degradation of NRF2 protein through competitive binding to KEAP1 protein,” The Journal of Biological Chemistry, vol. 287, no. 9, pp. 6539–6550, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. V. I. Korolchuk, F. M. Menzies, and D. C. Rubinsztein, “Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems,” FEBS Letters, vol. 584, no. 7, pp. 1393–1398, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Wang, M. Chen, J. Yang, and Z. Zhang, “LC3 fluorescent puncta in autophagosomes or in protein aggregates can be distinguished by FRAP analysis in living cells,” Autophagy, vol. 9, no. 5, pp. 756–769, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Bjorkoy, T. Lamark, S. Pankiv, A. Overvatn, A. Brech, and T. Johansen, “Monitoring autophagic degradation of p62/SQSTM1,” Methods in Enzymology, vol. 452, pp. 181–197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Lau, W. Tian, S. A. Whitman, and D. D. Zhang, “The predicted molecular weight of Nrf2: it is what it is not,” Antioxidants & Redox Signaling, vol. 18, no. 1, pp. 91–93, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. H. K. Bryan, A. Olayanju, C. E. Goldring, and B. K. Park, “The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation,” Biochemical Pharmacology, vol. 85, no. 6, pp. 705–717, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. A. D. Kraft, D. A. Johnson, and J. A. Johnson, “Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult,” The Journal of Neuroscience, vol. 24, no. 5, pp. 1101–1112, 2004. View at Google Scholar
  50. M. Belanger and P. J. Magistretti, “The role of astroglia in neuroprotection,” Dialogues in Clinical Neuroscience, vol. 11, no. 3, pp. 281–295, 2009. View at Google Scholar
  51. P. S. Baxter and G. E. Hardingham, “Adaptive regulation of the brain’s antioxidant defences by neurons and astrocytes,” Free Radical Biology and Medicine, vol. 100, pp. 147–152, 2016. View at Publisher · View at Google Scholar · View at Scopus
  52. K. F. Bell, B. Al-Mubarak, J. H. Fowler et al., “Mild oxidative stress activates Nrf2 in astrocytes, which contributes to neuroprotective ischemic preconditioning,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 1, pp. E1–E2, 2011, author reply E3-4. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Hong, S. Sha, L. Zhou, C. Wang, J. Yin, and L. Chen, “Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons,” Cell Death & Disease, vol. 6, article e1832, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. L. Yang, H. Yao, X. Chen, Y. Cai, S. Callen, and S. Buch, “Role of sigma receptor in cocaine-mediated induction of glial fibrillary acidic protein: implications for HAND,” Molecular Neurobiology, vol. 53, no. 2, pp. 1329–1342, 2016. View at Google Scholar
  55. S. Sha, W. J. Qu, L. Li, Z. H. Lu, L. Chen, and W. F. Yu, “Sigma-1 receptor knockout impairs neurogenesis in dentate gyrus of adult hippocampus via down-regulation of NMDA receptors,” CNS Neuroscience & Therapeutics, vol. 19, no. 9, pp. 705–713, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. Y. H. Han, H. J. Moon, B. R. You, and W. H. Park, “The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH,” Oncology Reports, vol. 22, no. 1, pp. 215–221, 2009. View at Google Scholar
  57. H. S. Park, Y. Jun do, C. R. Han, H. J. Woo, and Y. H. Kim, “Proteasome inhibitor MG132-induced apoptosis via ER stress-mediated apoptotic pathway and its potentiation by protein tyrosine kinase p56lck in human Jurkat T cells,” Biochemical Pharmacology, vol. 82, no. 9, pp. 1110–1125, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. K. T. Bush, A. L. Goldberg, and S. K. Nigam, “Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance,” The Journal of Biological Chemistry, vol. 272, no. 14, pp. 9086–9092, 1997. View at Google Scholar
  59. T. Omi, H. Tanimukai, D. Kanayama et al., “Fluvoxamine alleviates ER stress via induction of sigma-1 receptor,” Cell Death & Disease, vol. 5, article e1332, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. D. Lindholm, H. Wootz, and L. Korhonen, “ER stress and neurodegenerative diseases,” Cell Death and Differentiation, vol. 13, no. 3, pp. 385–392, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. T. Hayashi, E. Hayashi, M. Fujimoto, H. Sprong, and T. P. Su, “The lifetime of UDP-galactose:ceramide galactosyltransferase is controlled by a distinct endoplasmic reticulum-associated degradation (ERAD) regulated by sigma-1 receptor chaperones,” The Journal of Biological Chemistry, vol. 287, no. 51, pp. 43156–43169, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Miki, K. Tanji, F. Mori, and K. Wakabayashi, “Sigma-1 receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington’s disease,” Neurobiology of Disease, vol. 74, pp. 25–31, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. Miki, F. Mori, T. Kon et al., “Accumulation of the sigma-1 receptor is common to neuronal nuclear inclusions in various neurodegenerative diseases,” Neuropathology, vol. 34, no. 2, pp. 148–158, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. K. Araki and K. Nagata, “Protein folding and quality control in the ER,” Cold Spring Harbor Perspectives in Biology, vol. 3, no. 11, article a007526, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Hamasaki, N. Furuta, A. Matsuda et al., “Autophagosomes form at ER-mitochondria contact sites,” Nature, vol. 495, no. 7441, pp. 389–393, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. H. R. Schmidt, S. Zheng, E. Gurpinar, A. Koehl, A. Manglik, and A. C. Kruse, “Crystal structure of the human sigma receptor,” Nature, vol. 532, no. 7600, pp. 527–530, 2016. View at Publisher · View at Google Scholar · View at Scopus
  67. T. Hayashi, “Conversion of psychological stress into cellular stress response: roles of the sigma-1 receptor in the process,” Psychiatry and Clinical Neurosciences, vol. 69, no. 4, pp. 179–191, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Mori, T. Hayashi, and T. P. Su, “Compromising sigma-1 receptors at the endoplasmic reticulum render cytotoxicity to physiologically relevant concentrations of dopamine in a nuclear factor-kappaB/Bcl-2-dependent mechanism: potential relevance to Parkinson’s disease,” The Journal of Pharmacology and Experimental Therapeutics, vol. 341, no. 3, pp. 663–671, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. N. Natsvlishvili, N. Goguadze, E. Zhuravliova, and D. Mikeladze, “Sigma-1 receptor directly interacts with Rac1-GTPase in the brain mitochondria,” BMC Biochemistry, vol. 16, p. 11, 2015. View at Publisher · View at Google Scholar · View at Scopus
  70. J. Meunier and T. Hayashi, “Sigma-1 receptors regulate Bcl-2 expression by reactive oxygen species-dependent transcriptional regulation of nuclear factor kappaB,” The Journal of Pharmacology and Experimental Therapeutics, vol. 332, no. 2, pp. 388–397, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Dong, Y. Ma, Z. Ren et al., “Sigma-1 receptor modulates neuroinflammation after traumatic brain injury,” Cellular and Molecular Neurobiology, vol. 36, no. 5, pp. 639–645, 2016. View at Google Scholar
  72. K. F. Bell, B. Al-Mubarak, M. A. Martel et al., “Neuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2,” Nature Communications, vol. 6, p. 7066, 2015. View at Publisher · View at Google Scholar · View at Scopus
  73. Y. Tanaka, L. M. Aleksunes, R. L. Yeager et al., “NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet,” The Journal of Pharmacology and Experimental Therapeutics, vol. 325, no. 2, pp. 655–664, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Meunier, J. Ieni, and T. Maurice, “The anti-amnesic and neuroprotective effects of donepezil against amyloid beta 25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor,” British Journal of Pharmacology, vol. 149, no. 8, pp. 998–1012, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Wang, A. Saul, P. Roon, and S. B. Smith, “Activation of the molecular chaperone, sigma 1 receptor, preserves cone function in a murine model of inherited retinal degeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 26, pp. E3764–E3772, 2016. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Narasimhan, L. Mahimainathan, M. L. Rathinam, A. K. Riar, and G. I. Henderson, “Overexpression of Nrf2 protects cerebral cortical neurons from ethanol-induced apoptotic death,” Molecular Pharmacology, vol. 80, no. 6, pp. 988–999, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. A. Lau, X. J. Wang, F. Zhao et al., “A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62,” Molecular and Cellular Biology, vol. 30, no. 13, pp. 3275–3285, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. L. Nguyen, N. Kaushal, M. J. Robson, and R. R. Matsumoto, “Sigma receptors as potential therapeutic targets for neuroprotection,” European Journal of Pharmacology, vol. 743, pp. 42–47, 2014. View at Publisher · View at Google Scholar · View at Scopus